KMKoji Miyahara

Koji Miyahara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koji Miyahara has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An Atypical Case of Angioedema With Normal C1‐Inhibitor Responding to Both C1‐Inhibitor Concentrate and Omalizumab

    by Koji Miyahara, Marie Matsumoto, Masaki Kunihiro, Yoichiro Toi, Michihiro Hide

    Angioedema is classified into mast cell‐mediated and bradykinin‐mediated types. Mast cell‐mediated angioedema (AE‐MC) frequently presents with wheals and may respond to antihistamines and/or corticosteroids. In contrast, bradykinin‐mediated angioedema (AE‐BK) neither accompanies urticaria nor responds to these treatments, but may respond to medications targeting bradykinin or molecules involved in its production pathway. Hereditary angioedema (HAE), a subtype of AE‐BK, includes a small population of HAE that exhibit normal C1 inhibitor (C1‐INH) levels, classified as HAE with normal C1‐INH (HAE‐nC1INH). However, genetic abnormalities are not identified in most cases, complicating the differentiation from AE‐MC. We present a case of a 41‐year‐old woman with recurrent gastrointestinal edema with abdominal pain, and marked swelling of the abdomen and extremities without C1‐INH deficiency. Neither family history nor genetic mutations were identified; however, her symptoms, including the lack of urticaria, and resistance to antihistamines and corticosteroids were consistent with AE‐BK. Considering the possibility of AE‐BK including HAE‐nC1INH, she received intravenous plasma‐derived C1‐INH (pdC1‐INH) from Day 112 (with Day 0 as her first visit) when an attack occurred, resulting in a substantial reduction of symptom severity. From Day 266, she was treated with q4w 300 mg omalizumab and her attack‐related symptoms largely reduced throughout the course without further administrations of pdC1‐INH. This case suggests a certain level of overlap between AE‐BK and AE‐MC, and the importance of trying anti‐immunoglobulin E medications for refractory angioedema.

  • Open Access

    Use of non‐invasive serum glycan markers to distinguish non‐alcoholic steatohepatitis from simple steatosis

    by Yasushi Yamasaki, Kazuhiro Nouso, Koji Miyahara, Nozomu Wada, Chihiro Dohi, Yuki Morimoto, Hideaki Kinugasa, Yasuto Takeuchi, Tetsuya Yasunaka, Kenji Kuwaki, et al.

    Background and Aims: Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non‐alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non‐alcoholic steatohepatitis (NASH) from simple steatosis (SS).Methods: We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high‐throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined.Results: Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis.Conclusion: We clearly demonstrated whole‐serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.


  • Open Access

    Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age

    by Koji Miyahara

    The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC). After development of sorafenib and its introduction as a therapeutic agent used in the clinic, several critical questions have been raised. Clinical parameters and biomarkers predicting sorafenib efficacy are the most important issues that need to be elucidated. Although it is difficult to know the responders in advance using conventional characteristics of patients, there are specific serum cytokines and/or gene amplification in tumor tissues that have been reported to predict efficacy of sorafenib. Risk and benefits of continuation of sorafenib beyond radiological progression is another issue to consider because no other standard therapy for advanced HCC as yet exists. In addition, effectiveness of the expanded application of sorafenib is still controversial, although a few studies have shed some light on combinational treatment with sorafenib for intermediate-stage HCC. Recently, over 50 relevant drugs have been developed and are currently under investigation. The efficacy of some of these drugs has been extensively examined, but none have demonstrated any superiority over sorafenib, so far. However, there are several drugs that have shown efficacy for treatment after sorafenib failure, and these are proceeding to further studies. To address these issues and questions, we have done extensive literature review and summarize the most current status of therapeutic application of sorafenib.


  • Open Access

    Serum glycan as a prognostic marker in patients with advanced hepatocellular carcinoma treated with sorafenib

    by Koji Miyahara, Kazuhiro Nouso, Yasuhiro Miyake, Shinichiro Nakamura, Shuntaro Obi, Maho Amano, Kazuko Hirose, Shin-Ichiro Nishimura, Kazuhide Yamamoto